Category Archives: News

EQT Life Sciences co-leads EUR 51 million Series B in Exciva to advance its Alzheimer’s therapy into clinical Phase 2

EQT Life Science

Neuron Signal Transfer original 1172027

  • Series B financing will support Exciva’s Phase 2 clinical trial of its lead candidate, Deraphan, for agitation associated with Alzheimer’s disease (AD)
  • Financing was co-led by EQT Life Sciences out of its LSP Dementia Fund, together with Gimv, with participation from Fountain Healthcare Partners, LifeArc, Carma Fund and Modi Ventures, as well as returning investors Andera Partners and LBBW
  • Investment underscores EQT Life Sciences’ commitment to high-impact neuroscience therapeutics, and will support Exciva’s ambition to address a significant unmet need in Alzheimer’s care

EQT Life Sciences is pleased to announce that its LSP Dementia Fund has co-led a EUR 51 million Series B in Exciva (the “Company”), a clinical-stage biopharmaceutical company developing novel therapies for behavioral symptoms associated with AD.

Neuropsychiatric symptoms such as agitation and other behavioral symptoms affect up to 90% of patients with severe AD, driving caregiver burden, healthcare utilization, and reduced quality of life. Despite the scale of the challenge, further compounded by a rapidly aging global population, therapeutic innovation has lagged behind. The Series B will support Exciva’s Phase 2 clinical trial evaluating Deraphan, the Company’s lead therapeutic candidate for agitation associated with AD. The trial will be conducted across the EU, United States, and Canada.

Exciva’s approach builds on strong scientific and clinical foundations. Deraphan, a combination of two clinically validated compounds including one new chemical entity, has demonstrated encouraging safety and tolerability in Phase 1 and offers the potential for a differentiated efficacy and safety profile relative to current treatment options, which are often limited by boxed warnings, side effects, or inconsistent outcomes.

François Conquet, CEO of Exciva, said: “We are delighted that we could attract funding from both new and existing investors, supporting our belief that our compound is promising. If the results of the Phase 2 trials are positive, it would be a significant milestone in symptomatic treatment options for patients with AD.”

Philip Scheltens, MD, PhD, Partner at EQT Life Sciences, said: “This investment illustrates the potential of Exciva to bring exciting innovation to a therapeutic area where Alzheimer’s patients have limited or no treatment options. We are delighted to co-lead this financing to help to realize Exciva’s potential, which stands out for both the quality of its science and the expertise of its team. We look forward to bringing this innovation to patients.”

Following the investment, EQT Life Sciences will be represented by Philip Scheltens as a Director and Juliette Lee as an Observer to the Board of the Company.

Contact
EQT Press Office, press@eqtpartners.com

Downloads

About EQT Life Sciences

EQT Life Sciences was formed in 2022 following an integration of LSP, a leading European life sciences and healthcare venture capital firm, into the EQT platform. As LSP, the firm raised over EUR 3.0 billion (USD 3.5 billion) and supported the growth of more than 150 companies since it started to invest over 30 years ago. With a dedicated team of highly experienced investment professionals, coming from backgrounds in medicine, science, business, and finance, EQT Life Sciences backs the smartest inventors who have ideas that could truly make a difference for patients. The LSP Dementia Fund (USD 297 million) started in 2020 and has a dedicated team of neurologists and neuroscientists focused on investing in therapeutics targeting neurodegenerative diseases.

For more information, go to https://eqtgroup.com/private-capital/life-sciences/

About Exciva

Exciva is a biopharmaceutical company, founded in 2016 by Drs Anton Bespalov, Hans Moebius and Rao Vepachedu to address neuropsychiatric symptoms in Alzheimer’s disease dementia and other brain disorders. Exciva uses its powerful discovery potential, which has led to the combination of two CNS-active compounds to treat agitation in patients living with Alzheimer’s disease dementia. Exciva is based in Heidelberg, Germany. www.exciva.com

Categories: News

Tags:

Carlyle leads financing for the acquisition of Comrod by Bridgepoint

Carlyle

Oslo, Norway, January 20, 2026 – Global investment firm Carlyle (NASDAQ: CG) today announced that its Global Credit platform has led a financing package to support the acquisition of Comrod, a leading European supplier of mission-critical defense communications and power systems, by Bridgepoint.

Founded in 1946 and headquartered in Norway, Comrod is a global supplier of advanced communications and power technology for defense, utility, and industrial applications. The company’s antennas, masts, amplifiers, and power systems are used across a range of NATO programs and military platforms. Comrod operates six production facilities globally, anchored by a well-invested manufacturing hub in Norway and supported by sites in France, Sweden, Hungary, and the United States.

The financing package will support Bridgepoint’s acquisition of the business, underpinning Comrod’s transition from a component supplier to a fully integrated tactical-communications subsystem provider. The transaction will also provide Comrod with flexible capital to continue to drive margin improvements through operational efficiency initiatives, pursue complementary bolt-on acquisitions, and scale internationally.

Comrod’s product portfolio is embedded in a range of long-term international military programs, with antennas, masts, and power systems that are critical to NATO’s land-based communications infrastructure. Against a backdrop of increasing European defense budgets, Comrod is well positioned to capitalize on this sustained investment cycle and deepen its role across key tactical-communications platforms.

Taj Sidhu, Head of European and Asian Private Credit at Carlyle, said: “Comrod is a key supplier of communications and power systems with deep integration across long-duration defense programs. As European defense investment accelerates, we see a compelling opportunity to support businesses that are central to the region’s security and infrastructure agenda. With more than three decades of experience investing across the global defense sector, Carlyle is well-positioned to help scale these mission-critical suppliers.”

Ole Gunnar Fjelde, CEO of Comrod, said: “This is a pivotal moment for Comrod as we scale into new markets and expand our capabilities across both defense and utility segments. Under Bridgepoint’s ownership and with Carlyle’s support, we are excited to continue to invest in innovation, grow our manufacturing footprint, and deepen relationships across our loyal customer base.”

—

About Carlyle

Carlyle (NASDAQ: CG) is a global investment firm with deep industry expertise that deploys private capital across its business and operates through three segments: Global Private Equity, Global Credit, and Carlyle AlpInvest. With $474 billion of assets under management as of September 30, 2025, Carlyle’s purpose is to invest wisely and create value on behalf of its investors, portfolio companies, and the communities in which we live and invest. Carlyle employs more than 2,400 people in 27 offices across four continents. Further information is available at carlyle.com. Follow Carlyle on LinkedIn at The Carlyle Group and on X at @OneCarlyle.

Media Contacts 

Carlyle:

Charlie Bristow

Tel: +44 (0) 7384 513568

Email: charlie.bristow@carlyle.com

Categories: News

Tags:

KKR-led Consortium Drives Further Investment in Sylvan

KKR

BEIJING–(BUSINESS WIRE)– Global investment firm KKR today announced the completion of an additional investment in Sylvan, a world-leading fungal biotechnology company (the “Company”), through funds managed by KKR with participation from new investors and a follow-on investment from existing investor, Novo Holdings, which increased its ownership stake in the Company as part of this round. Following the investment, KKR remains the majority investor in Sylvan.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260120305013/en/

Founded in 1932, Sylvan is a world-leading mushroom spawn and fungal biotechnology company. The company seeks to harness the potential of fungal systems to create sustainable solutions to address global challenges in food, health, agriculture, and materials. Today, the Company operates multiple production facilities around the world and serves customers across 65 countries.

This latest investment marks KKR’s continued commitment to supporting Sylvan’s next phase of expansion, including increasing production capacity, strengthening R&D capabilities, advancing new high-growth product categories, and deepening the Company’s presence across Asia’s rapidly industrializing mushroom and bio-products markets.

The KKR-led investment also included commitments from global investors, including TPG NewQuest, who served as lead investor in a GP-led transaction alongside KKR to support Sylvan, in addition to Ping’An Capital, China Post Insurance, Schroders Capital and Tsao Pao Chee. KKR is making its investment through its international and domestic funds, including its first Renminbi-denominated fund, which was established to facilitate investment by local investors.

Chris Sun, Partner and Head of China Private Equity at KKR, said: “Sylvan has delivered sustained growth under our strategic partnership, including strong expansion and advances in R&D and strategic acquisitions. We have worked closely with management to broaden Sylvan’s role in the global fungal biotechnology sector and beyond. KKR is pleased to welcome new investors from overseas and China to join us in supporting Sylvan to expand its platform and global reach.”

Jackie Qi, CEO of Sylvan, said: “KKR has been a trusted partner for Sylvan through our development, and we are pleased to have their continued support. This investment allows us to accelerate our ambition to become a global leader in fungal biotechnology solutions across strategies and regions. With the support and expertise of our investors, we have faith in Sylvan’s next phase of growth.”

About Sylvan

Sylvan is a fungal biotechnology company, unlocking the incredible potential of the Earth’s fungi systems. We believe these resilient fungi, having evolved over millions of years, hold the key to overcoming many of the problems our planet faces today and into the future. Our goal is simple: harness the power of fungi and create sustainable solutions to address global challenges in food, health, agriculture, and materials.

About KKR

KKR is a leading global investment firm that offers alternative asset management as well as capital markets and insurance solutions. KKR aims to generate attractive investment returns by following a patient and disciplined investment approach, employing world-class people, and supporting growth in its portfolio companies and communities. KKR sponsors investment funds that invest in private equity, credit and real assets and has strategic partners that manage hedge funds. KKR’s insurance subsidiaries offer retirement, life and reinsurance products under the management of Global Atlantic Financial Group. References to KKR’s investments may include the activities of its sponsored funds and insurance subsidiaries. For additional information about KKR & Co. Inc. (NYSE: KKR), please visit KKR’s website at www.kkr.com. For additional information about Global Atlantic Financial Group, please visit Global Atlantic Financial Group’s website at www.globalatlantic.com.

For more information, please contact:

Sylvan
Erica Wang
Erica.Wang@sylvaninc.com

KKR
Wei Jun Ong
Media@kkr.com

Source: KKR

 

Download PDF

Categories: News

Tags:

Ardian Clean Energy Evergreen Fund (ACEEF) expands Nordics portfolio

No Comments
Ardian

Ardian expands footprint in Sweden with deal to acquire 62MW Furukraft wind farm from ERG
• Investment and project execution led by Enordic Evergreen, ACEEF’s Nordic IPP platform
• Acquisition creates further scale and geographical diversification to Enordic Evergreen

Ardian, a global private investment firm, through its wholly owned local platform Enordic Evergreen, today announces its acquisition of Furukraft, a 62 MW wind farm in Sweden from leading Italian Independent Power Producer from renewable sources, ERG.

This investment reinforces Ardian’s commitment to advancing energy infrastructure in the Nordics and will enable additional value creation for Enordic Evergreen by enabling optimization at a platform level.

The wind farm benefits from strong market fundamentals including attractive price positioning in Sweden’s SE4 area and growing demand for renewable energy from industry, data centers and heating and transportation electrification. In addition, the project has entered an attractive long-term PPA with a local Swedish utility.

The investment benefits from OPTA, Ardian’s proprietary data analytics platform to optimize the management of renewables assets, to enhance performance and accelerate the next phase of value creation. During the investment process, OPTA was used to quantify the incremental benefit of Furukraft on our Nordics portfolio, in terms of cashflows volatility, enhancing our risk management strategy. Post-acquisition, the assets will be onboarded onto our OPTA platform for asset monitoring and further value creation. Ardian now tracks over 3GW of renewable assets through OPTA.

“This investment is an excellent strategic fit for ACEEF. It expands our presence in a highly attractive area of the Nordics, while complementing our existing portfolio and reinforcing Ardian’s commitment to strengthening renewable energy infrastructure. Leveraging our deep regional expertise and proven industrial strategy, we are well positioned to manage complex assets and generate long-term, sustainable value for our investors. With demand accelerating—particularly from data centers—this marks a pivotal moment for the Nordics market, and we are pleased to be at the forefront of expanding clean energy capacity through the ACEEF platform.” Federico Gotti Tedeschi, Managing Director Infrastructure, Ardian.

“This investment is an important milestone for Enordic Evergreen and for Ardian. This move brings us further scale and highly contracted business that will enable us to capitalize on platform-level strategies and active development. With presence in SE4 we will drive up our portfolio diversification and capture a new layer of flexibility. We want to thank the ACEEF team and OPTA’s analytical experts for their close collaboration with our local team to make this happen. Building on the strong foundation established by ERG, we look forward to driving the next phase of growth and operational optimization.” Timo Pohjakallio, Chief Executive Officer of Enordic Evergreen.

ACEEF is Infrastructure’s first open-ended clean energy fund, which was launched in early 2022 and whose fundraising reached €1.0bn at the closing in July 2023. The fund offers professional investors the opportunity to enhance their exposure to renewable assets and energy transition. The fund commits to making investments with an environmental objective as described in Article 9 fund of the EU Sustainable Finance Disclosure Regulation (SFDR) and invests globally, with a focus on Europe.

ACEEF will continue to focus on core renewable technologies – namely solar, wind and hydro, as well as emerging technologies across biogas, biomass, storage and energy efficiency. ACEEF currently manages 1.5GW of operating capacity across 5 platforms.

Enordic Evergreen is a 100% ACEEF-owned Nordic Independent Power Producer (IPP) committed to accelerating clean energy transition through long-term ownership, deep regional expertise, and strong local partnerships.

Ardian has been a pioneer in the energy transition, having started investing in renewable assets in 2007. Across all Infrastructure Funds at Ardian, the team manages more than 10GW of clean energy capacity in Europe and the Americas.

List of Participants

  • Ardian

    • M&A: ICECAPITAL
    • Legal: MAQS
    • Technical: AFRY, 8.2
    • Finance & Tax: Grant Thornton
    • Insurance: Marsh
    • ESG: Sweco

About Ardian

In a world of constant evolution, Ardian stands out for its ability to anticipate, adapt, and turn challenges into opportunities. As a global, diversified private markets firm with 22 offices and more than 350 investment professionals worldwide, we provide investment and customized solutions that reflect new economic dynamics and help our clients remain resilient in a changing world.
We deliver multi-local expertise and long-term performance for our investors and partners as well as shared value for the broader society. Since Ardian’s inception in 1996, our pioneering approach to diversification and our ability to offer tailor-made solutions at scale have remained the heart of our strategy.
Through commitment, knowledge and technology, we bring lasting value to our companies and contribute positively to the whole industry.
Ardian currently manages or advises $196bn for more than 1,890 clients worldwide across Private Equity, Real Assets, and Credit.
Ardian. Mastering change for lasting value.

ardian.com

Media contacts

Ardian

Headland

ardian@headlandconsultancy.com

Categories: News

Tags:

MMS Group has acquired TMI-Orion and TMI-USA activities to complement and reinforce JRI and CIET Pharma existing offer with validation solutions designed for harsh environment

IK Partners

The Metrology & Monitoring Solutions – MMS Group, a global leader in metrology and temperature monitoring for pharmaceutical, healthcare, food and other regulated industries, announces the strategic acquisition of TMI-Orion and TMI-USA activities. The integration of TMI solutions will strengthen JRI and CIET Pharma‘s portfolio with TMI‘s 30+ years of expertise in reliable, user-friendly loggers and software for harsh environment validation.

Pascal Vermeersch (President of MMS) is proud to onboard Alexander Kuhnel (current CEO of TMI-Orion) and Guillaume Favre (current CEO of TMI-USA) in MMS Group along with IK Partners. The MMS Group now employs circa 200 experts in 8 geographic areas with customers in 65 countries.

Measuring, monitoring and validation in all types of environments: JRI, TMI, and CIET Pharma are now covering the entire value chain for quality control and management

The TMI integration creates perfect synergies across all MMS entities for product R&D and software innovation, quality procedures, metrology and validation capabilities as well as customer support worldwide. The three companies offer complementary expertise: JRI’s IoT sensors and JRI-MySirius platform track temperature, humidity, CO₂, and particles in real time, complemented by TMI’s validation and qualification solution in extreme environment and CIET Pharma’s qualification, mapping, and compliance services.

3 companies offering a comprehensive & complementary range of services and products to meet the expectations of the most demanding customers, each with its own area of expertise

A Worldwide Coverage:

TMI and JRI share common DNA including metrology, quality management and customer satisfaction

Not only do TMI and JRI share complementary product offer and R&D expertise to address similar customers, but both companies have strong expertise in metrology, data collection, transfer, storage and integrity, quality management, compliance with regulations and standards (ISO 17025, GxP, FDA 21 CFR part 11, HACCP, FD X15-140, etc.), and share common priorities in customer support and satisfaction as well as social & environmental concerns.

TMI is an expert in validation & qualification with solutions adapted to harsh environment

TMI-Orion and TMI-USA are internationally recognized by pharmaceutical, healthcare, food and ceramic industry leaders worldwide for their high-precision embedded measurement solutions engineered for extreme environment use, serving customers such as GSK, Pfizer, Novartis, 3M, L’Oréal, Nestlé, Danone, Campbells’, Hormel Foods, Wienerberger, Imerys, Lingi, Saint-Gobain, and Airbus. Both companies are ISO 9001 certified.

Their autonomous data loggers excel in ultra-high temperatures (steam sterilization, ceramics and other high-heat industrial applications with proprietary thermal shields up to 1 300°C), cryogenic lyophilization / freeze-drying (-90°C), high pressure, and ATEX zones for over 30 years.

TMI includes a USA-based operating presence with full local capabilities

TMI-USA, based in Reston, Virginia, has an experienced team which performs the full scope TMI activities locally, from production to after sales services including customer support and metrology services with its internal metrology laboratory accredited in accordance with the recognized International Standard ISO/IEC 17025 for temperature, humidity, and pressure (with ANAB certification). TMI-USA can provide rapid response times for delivery, after sales and support to North American customers as well as LATAM customers.

TMI-Dynamics provides deep-underwater robotics equipment

Launched in 2018 as TMI’s robotics division, TMI-Dynamics specializes in underwater solutions (Electrical Actuators, & Electrical Manipulator Arms) for critical missionsofactuation, manipulation and inspection. This complementary business extends TMI’s extreme environment expertise to deep-underwater equipment.

——————————-

Pascal Vermeersch, President of MMS-JRI-TMI-CIET Pharma: “We are thrilled to welcome the TMI-Orion, TMI-USA, and TMI-Dynamics teams to offer our current and future customers a comprehensive range of complementary premium solutions: highly reliable, user-friendly loggers and software for validation or production processes in extreme environments. This acquisition is also a great opportunity to benefit from TMI-USA full operation in the USA including an accredited metrology lab in temperature, humidity, and pressure.”

Alexander Kuhnel, CEO of TMI-Orion and TMI-Dynamics: “Joining the MMS Group marks a historic milestone for TMI-Orion. Driven by shared values and natural synergies, this union will enable us to quickly combine our different areas of expertise to foster innovation and excellence in the services we provide to our customers. Fully aligned with the Group’s ambitions, all TMI teams are committed to this customer satisfaction-focused project.”

Guillaume Favre, CEO of TMI-USA: “The TMI-USA acquisition by MMS Group will empower business development actions targeted to our domestic market as well as accelerate the improvement of the datalogger product line, development of new products and features, benefiting from JRI’s technical expertise. Customer satisfaction and customer service will remain TMI-USA’s priorities”

Pierre Gallix, Partner at IK Partners: “MMS Group’s acquisition of TMI enlarges MMS range of solutions and strengthens its US market expansion. Customer satisfaction and service excellence remain unwavering priorities for the Group. It also demonstrates MMS capacity to aggregate complementary and synergetic businesses to its platform.”

MMS Contact: Pascal Vermeersch – +33 (0)6 08 50 37 82 – pascal.vermeersch@group-mms.com

Press Contact: Communication Team – +33(0)1 39 96 33 35 – info@group-mms.com

About JRI

JRI is a metrology expert and designs, manufactures and maintains monitoring solutions for temperature, humidity, and other physical parameters adapted to the pharmaceutical industry, healthcare and food service sectors, meeting the quality requirements of the current regulations and standards (ISO 17025, GMP, GLP, FDA 21, CFR part 11, HACCP, etc.). JRI offers high-performance solutions as part of a recognized quality approach (COFRAC accreditations, HACCP, BPH, GBEA, etc.) .

Read More 

About CIET Pharma

CIET Pharma is specialized in qualification, mapping, sterilization, metrology and cryogenics, for the strictest customers in the pharmaceutical & cosmetic industry.

About IK Partners

IK Partners (“IK”) is a European private equity firm focused on investments in the Benelux, DACH, France, Nordics and the UK. Since 1989, IK has raised more than €20 billion of capital and invested in over 200 European companies. IK supports companies with strong underlying potential, partnering with management teams and investors to create robust, well-positioned businesses with excellent long-term prospects. For more information, visit ikpartners.com IK is an affiliate of Wendel. For more information, visit wendelgroup.com

Read More 

Categories: News

Tags:

Bain Capital Agrees Sale of Cora Resort and Spa in Greece to Fattal Hotel Group

BainCapital

LONDON and ATHENS, January 19, 2026 – Bain Capital, a leading global private investment firm, today announced the completion of the sale of Cora Resort and Spa, a five-star, 181-room resort in Afytos, Chalkidiki, Greece, to Fattal Hotel Group.

The investment was managed by Bain Capital’s Special Situations team in Europe and showcases the firm’s hands-on asset management capabilities in hospitality, spanning origination, development, operations and exit.

Bain Capital led a substantial refurbishment and repositioning of the hotel, supported by a €24 million investment programme, transforming the asset into a five-star destination resort with multiple restaurants and bars and a dedicated wellness centre. The property opened in July 2023 and has benefited from active operational oversight, including a management transition in 2024 that improved overall performance.

Rob Mangan, an Operating Partner at Bain Capital, said: “Together with our local partners, we took a very hands-on approach at Cora, executing a major refurbishment and repositioning programme and then actively managing the operations to drive performance. The result is a high-quality, five-star resort in one of Greece’s most attractive leisure markets. This sale reflects sustained investor appetite for well-located, well-invested hospitality assets, and we are pleased to hand the property to an owner with deep sector experience.”

Guy Vardi and Yaniv Amzaleg, M&A Managing Directors at Fattal Hotels, said: “Greece and the wider Mediterranean basin have shown exceptional performance in recent years, and expanding our footprint in this market remains a strategic priority. This asset, which will be rebranded as Meravia Hotel by Leonardo Limited Edition, represents a unique opportunity to introduce a high-end product in one of the most exciting hospitality markets today. Over the past three years, we have acquired more than 50 hotels across Europe and raised approximately €1 billion through our European partnerships to support our expansion strategy.  We would like to thank Bain Capital for their partnership throughout this acquisition process as we continue to pursue new opportunities in Southern and Western Europe.”

Bain Capital has extensive experience across hospitality at both the corporate and asset level, with a European track record of 8,200 keys across 54 properties in seven countries.

Advisors
Bain Capital: Karatza Partners (Legal)
Hotel was operated by SWOT Hospitality under Bain Capital ownership.
Fattal Hotels: Zepos & Yannopoulos (Legal) and EY (Financial)

About Cora Resort and Spa
Cora Resort and Spa is a five-star, 181-room resort located in Afytos, Chalkidiki, Greece, offering multiple restaurants and bars and a dedicated wellness centre.

About Fattal Hotels Group 
Fattal Hotels is a rapidly growing international hotel group that owns and operates over 320 hotels across more than 120 destinations worldwide, encompassing over 55,000 rooms. With a strong presence in 21 countries, including Germany, the UK & Ireland, Poland, Israel, Spain, the Netherlands, Austria, Italy, Greece, Cyprus, and France, the group continues to expand its global footprint across fantastic locations.

Fattal Hotels offers a diverse portfolio of accommodations, featuring leading brands such as Leonardo Hotels, Leonardo Royal Hotels, NYX lifestyle hotels, and all-inclusive resorts under the Leonardo banner. Additionally, its Leonardo Limited-Edition collection showcases a selection of uniquely curated and beautifully designed hotels, and Master collection of serviced apartments.

About Bain Capital 
Founded in 1984, Bain Capital is one of the world’s leading private investment firms. We are committed to creating lasting impact for our investors, portfolio companies, and the communities in which we live. As a private partnership, we lead with conviction and a culture of collaboration, advantages that enable us to innovate investment approaches, unlock opportunities, and create exceptional outcomes. Our global platform invests across five focus areas: Private Equity, Growth & Venture, Capital Solutions, Credit & Capital Markets, and Real Assets. In these focus areas, we bring deep sector expertise and wide-ranging capabilities. We have 24 offices on four continents, more than 1,900 employees, and approximately $205 billion in assets under management. To learn more, visit baincapital.com. Follow @BainCapital on LinkedIn and X (Twitter).

 

Media Contacts

 

 Charlyn Lusk (646) 502 3549 clusk@stantonprm.com

Categories: News

Tags:

KKR Increases Ownership Stake in Altavair

No Comments
KKR

NEW YORK & SEATTLE–(BUSINESS WIRE)– KKR, a leading global investment firm, and Altavair, a leader in commercial aviation leasing and financing, today announced a definitive agreement under which KKR will increase its ownership stake in Altavair and its sister company, AV AirFinance. KKR will fund the investment from its balance sheet.

The new investment deepens the long-term strategic partnership between KKR and Altavair, which invests across the global leased aircraft market. KKR-managed funds have committed more than $5 billion to aircraft leasing and lending transactions since the strategic partnership launched in 2018.

“We are pleased to build on our long-standing relationship with Altavair and reinforce our commitment to the aviation sector, which is an important area of opportunity for our Asset-Based Finance strategy,” said Daniel Pietrzak, Partner and Global Head of Private Credit at KKR. “We look forward to supporting Altavair further with our long-term capital as it continues to meet the evolving fleet needs of airlines and operators around the world.”

“Commercial aircraft assets have proved to be highly resilient across market cycles, supported by long-term demand for global air travel and strong contractual protections,” said Brandon Freiman, Partner and Head of North American Infrastructure at KKR. “Altavair is well positioned to execute at scale across the aviation ecosystem, and we are pleased to expand our partnership as the platform continues to grow.”

Altavair CEO Steve Rimmer said, “I am delighted to deepen our strategic partnership with KKR, and we appreciate the continued trust that this investment demonstrates. Our working relationship has developed and matured over the last 7 years, and KKR’s skillsets, expertise and market knowledge have been integral to helping grow Altavair into the successful platform that it is today.”

To support Altavair’s next phase of growth, Matthew Hoesley, Chief Commercial Officer, will expand his remit to become President & Chief Commercial Officer of Altavair, and Andrew Carpenter, Head of Tax & Accounting, will become Chief Financial Officer of Altavair.

About KKR

KKR is a leading global investment firm that offers alternative asset management as well as capital markets and insurance solutions. KKR aims to generate attractive investment returns by following a patient and disciplined investment approach, employing world-class people, and supporting growth in its portfolio companies and communities. KKR sponsors investment funds that invest in private equity, credit and real assets and has strategic partners that manage hedge funds. KKR’s insurance subsidiaries offer retirement, life and reinsurance products under the management of Global Atlantic Financial Group. References to KKR’s investments may include the activities of its sponsored funds and insurance subsidiaries. For additional information about KKR & Co. Inc. (NYSE: KKR), please visit KKR’s website at www.kkr.com. For additional information about Global Atlantic Financial Group, please visit Global Atlantic Financial Group’s website at www.globalatlantic.com.

About Altavair

Altavair L.P. is an aviation asset manager focusing on the acquisition of new and used commercial aircraft for leasing to domestic and international passenger airlines and cargo operators. Since its inception in 2003, Altavair has completed over $14.5 billion in commercial aircraft lease transactions with over 80 airline customers in 50 countries representing over 300 individual Boeing and Airbus aircraft. Altavair maintains offices in Seattle, Dublin, London, and Singapore. For more information, please visit www.altavair.com.

Lauren McCranie
media@kkr.com

Source: KKR

 

Download PDF

Categories: News

Tags:

Trustmoore announces strategic partnership with IK Partners to support next phase of growth

IK Partners

Trustmoore (“the Company”), an international fund and corporate services provider, today announces that it has entered into a strategic partnership with IK Partners (“IK”), a leading European private equity firm. IK will invest in the Company through its IK Small Cap IV Fund (“IK SC IV”), acquiring a majority stake. The active founders will reinvest significantly in the business alongside the existing management team. Financial terms of the transaction have not been disclosed and completion is subject to regulatory approvals.

Founded in 2005 and headquartered in Amsterdam, the Netherlands, Trustmoore is a boutique Fund and Corporate Services platform offering a comprehensive range of integrated solutions across four core areas: Fund Services, Corporate Services, Capital Markets and Private Clients. The Company benefits from strong competitive positioning and a well-established reputation for delivering high-quality, client-centric services.

Trustmoore serves a loyal and diversified base of reputable clients across 10 jurisdictions, with a substantial presence in Luxembourg and the Netherlands. The Company currently employs over 275 professionals across its offices and provides services to over 850 client groups.

A strategic step to support long-term growth

As client requirements continue to evolve, Trustmoore recognises the importance of partnering with an investor that shares its long-term vision as well as a commitment to delivering high-quality services and investing in its people.

Through its partnership with IK, the Company will be able to accelerate its development, building on strong organic momentum and executing targeted add-on acquisitions to enhance its capabilities and expand its service offering. Leveraging IK’s extensive experience in Financial Services and its proven track record of successfully executing buy-and-build strategies, built through a range of  partnerships including with  Vistra Group (Benelux), Advisense (Nordics), Qconcepts (Benelux), Dains (UK), Valoria Capital (France), Aspia (Nordics) and Yellow Hive (Benelux), Trustmoore is also well positioned to capitalise on opportunities within the growing global funds, corporate services and capital markets industry. Alongside this, the Company will continue to invest in its people, processes and technology.

Continuity for clients

Continuing to operate under its existing brand, strategy and leadership, with day-to-day services and client teams remaining unchanged, Trustmoore’s boutique mindset and client-first approach will be maintained. For clients, the partnership with IK is intended to reinforce the Company’s ability to deliver consistently high-quality, personal service, while providing greater capacity to support clients as they grow and face increasing complexity.

Steven Melkman and Roland Beunis, Founders of Trustmoore said “Over the past 20 years, Trustmoore has grown into a differentiated platform built on specialist expertise, personal service and a strong boutique mindset. As our clients’ needs continue to evolve and the market consolidates, it was important for us to find a partner that shared our long-term vision, commitment to quality and client-first approach. In IK, we have found exactly that. Its deep sector expertise and proven track record of supporting Financial Services businesses make IK the right partner to support the next phase of Trustmoore’s growth, while continuing to invest in our people and platform.”

Wouter Plantenga, CEO of Trustmoore, added: “Partnering with IK supports our ambition to build a stronger, more scalable platform while preserving Trustmoore’s core strengths. IK’s investment will enable us to further grow our organisation and significantly expand our capabilities and capacity. As a result, we will be even better positioned to support clients through growth, increasing regulatory complexity and cross-border activity, while maintaining the personalised service and specialist expertise they expect from Trustmoore. I look forward to working with the IK team during the next phase of our Company’s journey”.

Onne Tjerkstra, Partner at IK and Advisor to the IK SC IV Fund, commented: “Trustmoore has developed a high-quality platform that combines specialist expertise with a strong focus on personalised service across its core markets. We have been impressed by the founders’ strategic vision, the strength of the management team and the Company’s ability to grow organically against a backdrop of increasing regulatory complexity, while expanding into new jurisdictions and service lines. We look forward to partnering with the founders, Wouter and their team to support Trustmoore through its next phase of growth, capitalising on structural market tailwinds, executing an accelerated buy-and-build strategy and driving continued operational excellence.”

If you have any further questions, please contact:

Trustmoore
Pieter Ottevanger
Phone: +31 20 471 2707
pieter.ottevanger@trustmoore.com

IK Partners
Vidya Verlkumar
Phone: +44 (0)7787 558 193
vidya.verlkumar@ikpartners.com

Categories: News

Tags:

Bain Capital Successfully Completes $4 Billion Strategic Sale of WinTriX’s China Business

BainCapital

Beijing, January 16, 2026 — Bain Capital, a leading global private investment firm, today announced the successful completion of the sale of the China business of its data center portfolio company WinTriX DC Group (hereinafter “Chindata”) to a consortium led by Shenzhen Dongyangguang Industry Co., Ltd. (hereinafter “HEC”). The transaction, which values the business at approximately $4 billion, represents the largest transaction in the history of China’s data center industry.

The completion of the transaction marks a successful collaboration between Bain Capital and HEC, further underscoring strong industry confidence in the long-term growth potential of China’s digital infrastructure. Since Bain Capital’s initial investment in 2018, Chindata has grown into one of China’s leading hyperscale data center platforms, playing a critical role in supporting the rapid development of artificial intelligence, big data, and cloud computing.

“We are pleased to see this landmark transaction successfully completed,” said Drew Chen, a Partner at Bain Capital. “Chindata’s growth journey reflects Bain Capital’s long-term commitment to building and scaling category-leading businesses in partnership with strong management teams. We believe that HEC will build on this strong foundation and continue to advance Chindata into its next phase of growth.”

About Bain Capital
Founded in 1984, Bain Capital is one of the world’s leading private investment firms. We are committed to creating lasting impact for our investors, teams, businesses, and the communities in which we live. As a private partnership, we lead with conviction and a culture of collaboration, advantages that enable us to innovate investment approaches, unlock opportunities, and create exceptional outcomes. Our global platform invests across five focus areas: Private Equity, Growth & Venture, Capital Solutions, Credit & Capital Markets, and Real Assets. We have 24 offices on four continents, more than 1,945 employees, and approximately $215 billion in assets under management.

 

Media Contact

Asia / China

Zhen Trudy Wang

Categories: News

Tags:

Ardian signs an agreement to acquire a stake in IVB Wellness Lab, a fast‑growing and innovative supplements brand in Spain

Ardian

With this investment, the Growth team at Ardian partners with IVB’s founding team and existing minority shareholder Label Capital to accelerate IVB’s expansion in Spain and across Europe and support its product innovation strategy.

IVB Wellness Lab (“IVB”), a leading Spanish company in the research, development and distribution of science‑backed dietary supplements, welcomes Ardian, a global private investment firm, as a minority shareholder.

Founded in 2021 by Dr. Isabel Viña Bas, Valerio Soto Ferri, and Carlos Viña Bas, IVB has established itself as one of Spain’s most dynamic dietary supplement brands operating in a market driven by sustainable consumer trends around lifestyle and healthcare. Headquartered in Valencia, IVB differentiates through specific ingredient sourcing and a unique approach including clinical oversight and hospital partnerships.

Built on an asset‑light model, IVB offers a variety of products spanning essential dietary supplements (e.g., magnesium, omega 3) and advanced formulations targeting areas of general wellness such as women’s health. Initially launched as a digital‑first D2C (direct-to-consumer) brand, IVB has developed a strong and engaged community, and experienced industry-leading revenue growth. IVB has also quickly expanded into the pharmacy channel, already reaching c.2,000 pharmacies across Spain.

This partnership marks an important milestone in IVB’s growth journey, aiming to scale its operations in Spain, reinforce data-driven D2C growth, support its international expansion and strengthen its innovation capabilities.

Ardian will closely work with the co-founders and management team and leverage its expertise in scaling high‑growth consumer and health businesses to strengthen IVB’s commercial and operational foundations.
The transaction is expected to close in Q1 2026.

“IVB Wellness Lab stands out with product innovation designed to meet specific consumer needs, leveraging a strategic omnichannel distribution. We are proud to partner with this seasoned, ambitious and complementary founding team, to support IVB in achieving its growth objectives in Spain and abroad, leveraging Ardian’s talent network, health & digital expertise and international resources.” Alexis Saada, Head of Growth & Senior Managing Director, Ardian and Frédéric Quéru, Managing Director, Ardian.

“Since its inception, IVB has been redefining its category with unique science-anchored formulations, an authentic and highly engaged community and disciplined omnichannel execution. We’re excited to partner with Ardian on this next phase as they will bring valuable expertise to further support IVB’s European development.” Eléonore Oudea, Founding Partner, Label Capital and Gaspard de Sarnez, Founding Partner, Label Capital.

“We are extremely proud of how IVB Wellness Lab has evolved, driven by product excellence, scientific research, community engagement and disciplined execution. Partnering with Ardian marks a pivotal milestone for IVB and allows us to strengthen our foundations while accelerating our ambition in Spain and abroad. We look forward to building a long-term partnership that supports sustainable growth and preserves our mission that people “know more, fear less, and choose better”.” Isabel Viña, Valerio Soto & Carlos Viña, Co-Founders, IVB Lab.

List of participants

  • Ardian

    • Growth investment team: Alexis Saada, Frédéric Quéru, Alexandra Da Silva, Michelle Stitz, Noa Amzallag
    • Corporate lawyers: Garrigues Madrid (José Luis Ortín Romero, Luis Enrique Mata Palacios, Marta Ocón Barceló)
    • Financial due diligence: Eight Advisory (Christophe Delas, Gennat Mouline, Ilyas El Guermat, Armelle Pasquier)
    • Legal, labor and tax due diligence: Eight Advisory (Barbara Jouffa, Guillaume Rembry, Henriette Barrois, Lucie Goeller, Lucie Vernières)
    • Strategic due diligence: Digital Value (Arnaud de Baynast, Paul‑Henri Magnien, Youssef Meskine, Margarita Ichazo)

  • Label Capital

    • Label Capital: Véronique Morali, Eléonore Oudea, Gaspard de Sarnez, Gauthier Leyne
    • Corporate lawyers: White & Case (Simon Martin‑Gousset), Mayer Brown (Jean-Philippe Coiffard), EY (Javier Bustillo, Manuel Paz, Santiago Lopez)

  • IVB Wellness Lab

    • Co-founders: Isabel Viña Bas, Valerio Soto Ferri, Carlos Viña Bas
    • Corporate lawyers: Garrigues Valencia (Alejandro Micó Llorens, Paula Crespo, Ester García Camps)
    • Financial advisors: Alvarez & Marsal (Cédric Zana, Baptiste Rideau, Yassine Benslimane)

About Ardian

In a world of constant evolution, Ardian stands out for its ability to anticipate, adapt, and turn challenges into opportunities. As a global, diversified private markets firm with 22 offices and more than 350 investment professionals worldwide, we provide investment and customized solutions that reflect new economic dynamics and help our clients remain resilient in a changing world.
We deliver multi-local expertise and long-term performance for our investors and partners as well as shared value for the broader society. Since Ardian’s inception in 1996, our pioneering approach to diversification and our ability to offer tailor-made solutions at scale have remained the heart of our strategy.
Through commitment, knowledge and technology, we bring lasting value to our companies and contribute positively to the whole industry.
Ardian currently manages or advises $196bn for more than 1,890 clients worldwide across Private Equity, Real Assets, and Credit.
Ardian. Mastering change for lasting value.

www.ardian.com

About Label Capital

Label Capital is a Paris-based growth equity firm investing in the next generation of category-defining consumer brands across Europe and the US. We partner with founders improving daily life through superior products, brands & communities.

www.label-capital.com

About IVB Wellness Lab (“IVB”)

IVB Wellness Lab is an advanced, science-based supplementation laboratory focused on metabolic health, hormonal balance, and general well-being. Founded by Isabel Viña Bas, a medical doctor and researcher, the company was built with a clear objective: to help people understand what is happening in their bodies and to empower them to make better health decisions through education and targeted solutions. Guided by its mission: “know more, fear less, and choose better ” IVB Wellness Lab places scientific rigor and education at the center of its model. To ensure real-world impact, the company has an omnichannel strategy and works mainly through healthcare professionals such as pharmacies, physicians, and nutritionists, offering differentiated solutions for everyday health challenges.

www.ivbwellness.com

Press contacts

Ardian

Headland

ardian@headlandconsultancy.com 

Label Capital

contact@label-capital.com 

IVB WELLNESS LAB

María Fernández

mariafprensa@gmail.com+34606028842

Categories: News

Tags: